The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy

2.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

3.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

4.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

5.

Targeted radiation therapy shows near-complete response in rare sarcoma patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot